Lilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy?The Motley Fool • 06/08/26
Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trialsPRNewsWire • 06/08/26
Why Eli Lilly, In A Buy Zone, Is Still The 'Clear Winner' Of The 'Weight Loss Olympics'Investors Business Daily • 06/08/26
A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.The Motley Fool • 06/08/26
Novo Nordisk Real-World Data Supports Ozempic Against LLY's MounjaroZacks Investment Research • 06/08/26
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverageCNBC • 06/08/26
Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drugMarket Watch • 06/08/26
Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising.Barrons • 06/08/26
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopausePRNewsWire • 06/07/26
Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.Market Watch • 06/06/26
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complicationsPRNewsWire • 06/06/26
Eli Lilly Leads Medical Stocks To Watch, While Google Finds SupportInvestors Business Daily • 06/06/26
Why Health Care's Seasonal Tailwind Looks Especially Compelling This YearZacks Investment Research • 06/05/26
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s?Zacks Investment Research • 06/05/26
LLY Rises 14% in a Month: Should You Hold as Obesity Growth Continues?Zacks Investment Research • 06/05/26